HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

BenzingaMay 16 19:54

Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating

TipRanksMay 16 01:45

William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)

TipRanksMay 16 00:46

NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than

BenzingaMay 15 22:21

Cabaletta Bio | 10-Q: Quarterly report

SEC announcementMay 15 19:55 · Announcements

Cabaletta Bio Reveals Insights in Updated Corporate Presentation

TipRanksMay 15 19:22